咪唑啉受体
内分泌学
内科学
受体
尿囊素
细胞培养
化学
直线(几何图形)
生物
细胞生物学
生物化学
医学
遗传学
几何学
数学
作者
Ting Yang,Nan-Tsing Chiu,Hsien-Ching Chung,Chien‐Ning Hsu,W. Lee,J.-T. Cheng
出处
期刊:Hormone and Metabolic Research
[Georg Thieme Verlag KG]
日期:2012-05-15
卷期号:44 (12): 879-884
被引量:15
标识
DOI:10.1055/s-0032-1312624
摘要
Allantoin is known as the agonist of imidazoline receptor, especially the I2 subtype. Effect of allantoin on imidazoline I1 receptor (I1R) relating to reduction of blood pressure and its merit in steatosis are still obscure. Also, farnesoid X receptor (FXR) plays an important role in lipid homeostasis related to I1R activation. Thus, we administered allantoin into high fat diet (HFD)-fed mice showing hypertriglyceridemia and hypercholesterolemia. Allantoin significantly improved hyperlipidemia in HFD mice after 4 weeks of administration. Pretreatment with efaroxan, at a dose sufficient to inhibit I1R activation, attenuated the action of allantoin. In addition, in cultured HepG2 cells, allantoin increased the expression of farnesoid X receptor (FXR). The allantoin-induced FXR expression was blocked by efaroxan. Similar changes were observed in the expressions of FXR-targeted genes. Otherwise, allantoin also lowered systolic blood pressure (SBP) in HFD mice that can be blocked by efaroxan. Taken together, allantoin has an ability to activate I1R for improvement of metabolic disorders.
科研通智能强力驱动
Strongly Powered by AbleSci AI